Yes, interesting idea. That was also recently proposed in an article I cited on another thread here. The authors stated:It would be interesting to treat PCS patients with rituximab and see if there are any responders.
The paradox of chronic neuroinflammation, systemic immune suppression and autoimmunity after traumatic chronic spinal cord injury
.....Although some B cell depleting monoclonal antibodies (e.g., Rituxan®, Ocrelizumab®) fusion proteins or biologicals that regulate B-cell survival factors (e.g., BAFF and APRIL) have or are being tested as therapies for classical forms of autoimmune disease (Mackay, et al., 2003), similar strategies have not been tested in stroke, CNS injury or neurodegenerative disease.